Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- pSer/pThr binding domains in cell signaling
- Protein phosphorylation
- Historical perspective on tyrosine kinase signaling
- SH2 domains bind ligands via pTyr and pTyr+3
- The human kinome
- Ser and Thr kinases differ from Tyr kinases
- The new 'dogma' of signal transduction
- The concept
- 14-3-3 proteins are pSer/pThr-binding proteins
- Identifying new phospho-binding domains
- Recognizing overlapping consensus motifs
- The biology supports the biochemistry
- Architecture of polo-like kinases
- Structural basis for phospho-dependent binding
- Residues interacting with the phospho-peptide
- What does the Polo-box domain do in cells?
- The PBD targets Plk1 to mitotic substrates
- In the absence of a ligand, PBD inhibits Plk2
- Synergy between Cdk activity and the Plk1 PBD
- Identifying new pSer/pThr-binding domains (1)
- The DNA damage response pathway
- "High-throughput" analysis
- Screening 96,000 proteins
- Pax2-transactivation domain interacting protein
- The BRCT domains
- A subset of tandem BRCT domains
- pS+3 position- based phosphopeptides selection
- Basis for tandem BRCT-phosphopeptide binding
- Ser-1655 and Lys-1702 mediate interactions
- Cancer-associated mutations in BRCA1 BRCT
- Eliminating phosphopeptide binding function
- ATM amplification involves H2AX phosphorylation
- The phosphorylated C-terminus of H2AX
- BRCT domains are 'tuned' to bind to gamma H2AX
- Structural basis for MDC1 BRCT: H2AX binding
- Mutants cause loss of MDC1 foci after IR
- Identifying new pSer/pThr-binding domains (2)
- Proteins that contain pSer/pThr binding domains
- Coordination of mitotic signaling complexes
- Evolutionary difference
- pSer/pThr binding domains control cell cycle
- Conclusions
- Acknowledgements
Topics Covered
- Protein phosphorylation
- Historical perspective on signaling by tyrosine kinases
- The human kinome
- How can phosphorylation control enzyme activity
- The new 'dogma' of signal transduction by serine/threonine kinases
- New phospho-binding domains
- Polo family kinases together with cyclin-dependent kinases play many roles throughout mitosis
- Architecture of polo-like kinases
- Structural basis for phospho-dependent binding
- What does the polo-box domain do in cells
- A proteomic approach to identifying new phospho-Ser/Thr-binding domains
- The DNA damage response pathway
- BRCA1
- Cancer associated mutations
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Yaffe, M. (2008, August 14). Phosphoserine/threonine binding domains: molecular integrators of protein kinase signaling in cell cycle control and cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/TLCX4134.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Michael Yaffe has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Phosphoserine/threonine binding domains: molecular integrators of protein kinase signaling in cell cycle control and cancer
Published on August 14, 2008
86 min
A selection of talks on Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Michael Yaffe from the MIT Center for
Cancer Research and the Departments of Biology and Biological Engineering.
And the title of my talk is "Phosphoserine and
Phosphothreonine Binding Domains Molecular Integrators of Protein Kinase
Signaling in Cell Cycle Control and Cancer".
0:18
What I'd like to tell you about is how
phosphoserine and phosphothreonine binding domains are involved in
orchestrating cells signaling with a particular focus on
cell cycle control and the response to cells to DNA damage.
It's well established that in response to various types of stimuli,
such as growth factor stimulation or DNA damage,
protein kinase has become activated in cells and phosphorylate,
a subset of proteins within the cell
and these phosphorylated substrates then are believed to be
responsible for many of the molecular effects that follow after the initial stimulus.
Some of these molecular effects include things like cell cycle checkpoints,
DNA damage repair, or the decision of a cell to undergo
apoptosis or withdraw from the cell cycle and senensence.
There is also integration of the cell cycle and the DNA damage checkpoint pathways
so that it appears not only due to
cell cycle checkpoints inactivate progression through the cell cycle,
but progression through the cell cycle may be
required in order to activate DNA damage checkpoints.
The unique aspect of our approach to this problem has been making the claim that
phosphorylation of substrates by protein kinases alone may
not be enough to elicit the particular molecular effects that are observed.
Instead, it appears to be the interaction of
the phosphorylated substrates with specific phosphoserine,
phosphothreonine or phosphotyrosine-binding domains that
coordinates the action of the protein kinase with the molecular effect that we observe.
Therefore, it becomes important for us to not only
identify the phosphopeptide-binding domains and their substrates,
but to also use systems biology approaches to understand
the activation of different protein kinases as a function of time,
in order to understand how signalling networks are coordinated in time and space.
It's well established that protein phosphorylation
Hide